PL2964768T3 - System ekspresji komórkowej - Google Patents

System ekspresji komórkowej

Info

Publication number
PL2964768T3
PL2964768T3 PL14761184T PL14761184T PL2964768T3 PL 2964768 T3 PL2964768 T3 PL 2964768T3 PL 14761184 T PL14761184 T PL 14761184T PL 14761184 T PL14761184 T PL 14761184T PL 2964768 T3 PL2964768 T3 PL 2964768T3
Authority
PL
Poland
Prior art keywords
expression system
cell expression
cell
expression
Prior art date
Application number
PL14761184T
Other languages
English (en)
Inventor
Noelle SUNSTROM
Original Assignee
Neuclone Biologics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013900804A external-priority patent/AU2013900804A0/en
Application filed by Neuclone Biologics Pty Ltd filed Critical Neuclone Biologics Pty Ltd
Publication of PL2964768T3 publication Critical patent/PL2964768T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14761184T 2013-03-08 2014-02-17 System ekspresji komórkowej PL2964768T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2013900804A AU2013900804A0 (en) 2013-03-08 A cell expression system
AU2013900808A AU2013900808A0 (en) 2013-03-08 A cell expression system
PCT/AU2014/000129 WO2014134657A1 (en) 2013-03-08 2014-02-17 A cell expression system
EP14761184.2A EP2964768B1 (en) 2013-03-08 2014-02-17 A cell expression system

Publications (1)

Publication Number Publication Date
PL2964768T3 true PL2964768T3 (pl) 2021-01-11

Family

ID=51490471

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14761184T PL2964768T3 (pl) 2013-03-08 2014-02-17 System ekspresji komórkowej

Country Status (10)

Country Link
US (5) US9404078B2 (pl)
EP (1) EP2964768B1 (pl)
JP (1) JP6464100B2 (pl)
KR (1) KR20150125994A (pl)
AU (2) AU2014225272B2 (pl)
CA (1) CA2904146C (pl)
MY (1) MY186731A (pl)
PL (1) PL2964768T3 (pl)
SG (1) SG11201506926SA (pl)
WO (1) WO2014134657A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
PL2964768T3 (pl) 2013-03-08 2021-01-11 Neuclone Biologics Pty Ltd System ekspresji komórkowej
US20160017277A1 (en) * 2013-03-08 2016-01-21 Neuclone Biologics Pty Ltd Cell culture media composition and methods of producing thereof
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015195049A1 (en) * 2014-06-18 2015-12-23 Agency For Science, Technology And Research Novel promoters for high level expression
PT3167065T (pt) * 2014-07-09 2020-07-01 Lupin Ltd Sistema de expressão bacteriana dual cistrónica
CN105820246A (zh) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型重组抗TNFα嵌合单克隆抗体制备方法及用途
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
EP3408397B1 (en) 2016-01-27 2020-07-15 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
EP3408394B1 (en) * 2016-01-27 2020-08-12 Total Raffinage Chimie Multigene expression in microalgae

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US772031A (en) * 1904-05-14 1904-10-11 Edward Ermold Envelop.
IL102929A (en) 1992-08-24 1996-11-14 Interpharm Lab Ltd Serum-free medium for mammalian cells
AUPN442295A0 (en) 1995-07-26 1995-08-17 Commonwealth Scientific And Industrial Research Organisation Regulated autocrine growth of mammalian cells
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
AU2002356749A1 (en) 2001-11-28 2003-06-10 Hermann Katinger Process for the production of polypeptides in mammalian cell cultures
US7262025B2 (en) 2002-06-18 2007-08-28 Zymogenetics, Inc. Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter
US8669109B2 (en) 2003-08-19 2014-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methods of producing proteins in Chinese hamster ovary (CHO) cells
AU2004270765B2 (en) 2003-09-09 2010-03-04 Acyte Biotech Pty Ltd Rodent expression systems utilising Polyoma Virus and Epstein Barr Virus sequences
KR100772031B1 (ko) * 2005-10-22 2007-10-31 (주)리즈바이오텍 성장 호르몬에 의한 재조합 단백질의 생산량 증가 방법
JP2011525800A (ja) * 2008-06-27 2011-09-29 ノボ ノルディスク ヘルス ケア アーゲー 長時間にわたる循環半減期を有するｎ−グリコシル化ヒト成長ホルモン
PL2964768T3 (pl) 2013-03-08 2021-01-11 Neuclone Biologics Pty Ltd System ekspresji komórkowej
US20160017277A1 (en) 2013-03-08 2016-01-21 Neuclone Biologics Pty Ltd Cell culture media composition and methods of producing thereof

Also Published As

Publication number Publication date
EP2964768B1 (en) 2020-07-22
US9404078B2 (en) 2016-08-02
US20160244799A1 (en) 2016-08-25
US9957541B2 (en) 2018-05-01
JP6464100B2 (ja) 2019-02-06
US20200040371A1 (en) 2020-02-06
AU2014225272A1 (en) 2015-09-24
CA2904146A1 (en) 2014-09-12
US20220002776A1 (en) 2022-01-06
US20180100176A9 (en) 2018-04-12
WO2014134657A1 (en) 2014-09-12
AU2016200361A1 (en) 2016-02-11
JP2016510592A (ja) 2016-04-11
AU2014225272B2 (en) 2015-10-22
SG11201506926SA (en) 2015-09-29
EP2964768A4 (en) 2016-11-09
KR20150125994A (ko) 2015-11-10
CA2904146C (en) 2023-03-21
AU2016200361B2 (en) 2017-12-14
EP2964768A1 (en) 2016-01-13
US20160017281A1 (en) 2016-01-21
US20180195102A1 (en) 2018-07-12
MY186731A (en) 2021-08-14

Similar Documents

Publication Publication Date Title
HK1223554A1 (zh) 細胞
SG11201506926SA (en) A cell expression system
AU356417S (en) Battery
EP2973571A4 (en) MEMORY SYSTEM
EP2983268A4 (en) BATTERY SYSTEM
EP2945204A4 (en) BATTERY BOX
EP2975668A4 (en) BATTERY SYSTEM
EP2988346A4 (en) CELL HOUSING
HK1224433A1 (zh) 鋰硫電池
GB201306883D0 (en) A retention arrangement
EP2988354A4 (en) FUEL CELL SYSTEM
SG11201600978VA (en) A fuel cell unit
GB201301783D0 (en) A fuel system
GB201413570D0 (en) Energy system
SG11201509409YA (en) A reversible thermo-initiated system
GB2515463B (en) A fuel cell system
GB201312332D0 (en) Cell locations
GB201310031D0 (en) Cell
EP2953200A4 (en) BATTERY
SG11201508928UA (en) A fuel cell system
EP2977432A4 (en) SYSTEM FOR GENERATING GASIFIED GAS
EP3073559A4 (en) FUEL CELL SYSTEM
GB201518278D0 (en) Operation of a fuel cell system
AU2013900808A0 (en) A cell expression system
AU2013900804A0 (en) A cell expression system